Management of portal hypertensive gastropathy and other bleeding

Woo Jin Chung
Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea

A major cause of cirrhosis related morbidity and mortality is the development of variceal bleeding, a direct consequence of portal hypertension. Less common causes of gastrointestinal bleeding are peptic ulcers, malignancy, angiodysplasia, etc. Upper gastrointestinal bleeding has been classified according to the presence of a variceal or non-variceal bleeding. Although non-variceal gastrointestinal bleeding is not common in cirrhotic patients, gastro-duodenal ulcers may develop as often as non-cirrhotic patients. Ulcers in cirrhotic patients may be more severe and less frequently associated with chronic intake of non-steroidal anti-inflammatorv drugs, and may require more frequently endoscopic treatment. Portal hypertensive gastropathy (PHG) refers to changes in the mucosa of the stomach in patients with portal hypertension. Patients with portal hypertension may experience bleeding from the stomach, and pharmacologic or radiologic interventional procedure may be useful in preventing re-bleeding from PHG. Gastric antral vascular ectasia (GAVE) seems to be different disease entity from PHG, and endoscopic ablation can be the first-line treatment. (Clin Mol Hepatol 2014;20:1-5)

Keywords: Gastric antral vascular ectasia; Liver cirrhosis; Portal hypertensive gastropathy

INTRODUCTION

Gastrointestinal (GI) bleeding is regarded as a life threatening condition in which mortality rates were reported up to 4-15%1-4 and in cases of cirrhotic patients, there are higher chances for GI bleeding compared with the non-cirrhotic patients. GI bleeding with cirrhotic patients is mostly caused by esophageal varix or gastric varix. Other causes for bleeding are gastric or duodenal ulcer similarly in cases of non-cirrhotic patients. Other minor causes for GI bleeding are portal hypertensive gastropathy (PHG) and gastric antral vascular ectasia (GAVE), etc. As the mechanisms of PHG or GAVE are still unclear and the treatment can be different according to the causes. We need more data for understanding their pathophysiology.

GI bleeding in cirrhotic patients

GI bleeding in cirrhotic patients is generally classified into variceal bleeding and non-variceal bleeding. Non-variceal bleeding is known to consist of 30-40% of total upper GI bleeding and its main causes are reported to be gastric or duodenal ulcer.5,6

When we analyzed the data of 227 patients who visited emergency room in Dongsan hospital, Keimyung university between Jan. 2010 and Dec. 2011 due to hematemesis or melena and diagnosed as GI bleeding by endoscopic examination, 26.8% of patients were cirrhotic and the other 73.2% of patients were non-cirrhotic patients (Fig. 1).

The causes of bleeding in non-cirrhotic patients were gastric ul-
cer (54.2%), duodenal ulcer (12.7%), Mallory-Weiss syndrome (12.7%), gastric cancer (10.8%), gastric and duodenal ulcer (5.4%), Dieulafoy’s lesion (2.4%) and angiodysplasia (1.2%), etc. In case of cirrhotic patients, the causes were esophageal varix bleeding (50%), gastric ulcer (24.2%), duodenal ulcer (7.6%), gastric varix (4.5%), etc. When ruled out the variceal bleeding, the portions of causes were gastric ulcer (64%), duodenal ulcer (20%), Mallory-Weiss syndrome (4%), gastric and duodenal ulcer (4%), etc (Fig. 2).

The mechanisms of gastric or duodenal ulcer in the cirrhotic patients are reported to be different compared with the cases of non-cirrhotic patients. In case of non-cirrhotic patients, the main causes of ulcer bleeding are old age, intake of chronic non-steroid anti-inflammatory analgesic drugs and *Helicobacter pylori* infection, etc. but in case of the cirrhotic patients, the main causes were reported to be alcohol intake or portal hypertension. Besides, the bleeding can take place by PHG and GAVE.

**Peptic ulcer in cirrhotic patients**

The prevalence of peptic ulcer in the cirrhotic patients is reported in the range of 4.3-49% and in Korean studies, its prevalence was in the range of 24.3% to 38.3% which shows higher compared with the reports from western countries.

In liver cirrhosis, the incidence of peptic ulcer increases, longer treatment duration is needed when treat with H2 receptor antagonists, and, the higher recurrence rate has been reported within a year compared with the non-cirrhotic patients (17-20% vs. 21-54.5%).

As congestion and impaired angiogenesis are caused by change in the microcirculation of gastric mucosa due to portal hypertension, the defense mechanisms for gastric acid or bile reflux, etc. are impaired in the cirrhotic patients.

*Helicobacter pylori* infection is reported to play an important role as the risk factor of peptic ulcer development in cirrhotic patients. However, its recurrence patterns in cirrhotic patients after eradication of *Helicobacter pylori* showed somewhat different from the non-cirrhotic patients. Recurrence rates of duodenal ulcer after one year of eradication in cirrhotic patients was 58% and also another study reported the 41% of ulcer recurrence rate within 2 years after eradication in cirrhotic patients. So, these data...
show that the risk factors of the recurrence of peptic ulcer in cirrhotic patients would be correlated with degree of impaired liver function or the presence of variceal bleeding rather than the success of *Helicobacter pylori* eradication.\(^\text{16}\)

**Portal hypertensive gastropathy in cirrhotic patients**

PHG is the change in the gastric mucosa of the patient with portal hypertension, and mucosal changes of PHG can be defined as the presence of mucosal friability and dilated blood vessels in the mucosal surface (Fig. 3).

The frequency of PHG has been variously reported in the range of 9-80% according to each studies since the coherent diagnostic criteria was not available.\(^\text{17-20}\) The severity of PHG may be positively correlated with the disease duration, the presence of esophageal or gastric varix, size of varix and the history of sclerotherapy. But actually, incidence of GI bleeding in PHG is relatively rare and the cases to cause severe GI bleeding are extremely rare.\(^\text{21}\)

Recently, the diagnosis for PHG or classification of its severity is carried out by the 2-step classification suggested by Baveno consensus workshop (Table 1).\(^\text{22}\) While keeping track of its progress for 18 months on average, about 29% of cases showed no significant change, 23% or so showed significant progression, 23% or so showed improvement and other one fourth of cases showed wax and wane depends on patients situation.\(^\text{21}\)

Regurgitant blood flow to the stomach due to portal hypertension is considered as primary cause of PHG.\(^\text{17,20}\) However, the relationship between increased level of portal blood pressure and the severity of PHG is still unclear.\(^\text{17,18,21}\) The imbalance between offense factors and defense factors of gastric mucosa can be the other cause of development of clinically significant GI bleeding in PHG.\(^\text{18}\)

It is reported that about 10% of PHG cause anemia due to the chronic blood loss, 2.5% of patients experienced acute bleeding. Medications for reducing portal blood pressure may be needed in some selective patients because mortality rate related to acute GI bleeding reaches of 12.5%.\(^\text{21}\) Nonselective beta blockers are reported to improve the patients’ quality of life by reducing the severity of PHG and to prevent rebleeding.\(^\text{24}\) Medications such as octreotide and somatostatin used for the treatment of portal hypertension are reported to be very effective for control of acute GI bleeding.\(^\text{25}\) In additions, transjugular intrahepatic portosystemic shunt formation which reduce portal blood pressure is also report-

| Parameter                                | Score |
|------------------------------------------|-------|
| Mucosal mosaic pattern                   |       |
| Mild                                     | 1     |
| Severe                                   | 2     |
| Red markings                             |       |
| Isolated                                 | 1     |
| Confluent                                | 2     |
| Gastric antral vascular ectasia          |       |
| Absence                                  | 1     |
| Presence                                 | 2     |

Mild portal hypertensive gastropathy ≤3.
Severe portal hypertensive gastropathy ≥4.

Figure 3. Representative images of mild (A) and severe (B) portal hypertensive gastropathy.
ed to improve the severity of PHG and to decrease the frequency of rebleeding.26

Because relationship between Helicobacter pylori infection and PHG is not clearly identified, the proper evidence about need of eradication for the management of PHG is insufficient.27 In addition, the evidences of proton pump inhibitors to reduce the frequency of ulcer formation and related bleeding caused by PHG are to be proved.28

Gastric antral vascular ectasia in cirrhotic patients

GAVE is a cause of chronic GI bleeding and iron deficiency anemia while related to the expansion of small blood vessels in gastric antrum. Dilated blood vessels are observed in the form of red straight line at the antrum under endoscopic examination. And pathologically, the specific findings such as dilated capillaries, fibromuscular dysplasia, fibrin thrombus, and fibrohyalinosis are observed.29

Compared with body part in case of PHG, affected site is gastric antrum in GAVE. Treatment to reduce the portal blood pressure can improve the PHG. But decrease of portal blood flow cannot improve the GAVE. Therefore, PHG and GAVE may be classified into the different disease category.30-32

About 30% of patients with GAVE also are cirrhotic29 and around 2.5% of decompensated cirrhotic patients who need liver transplantation are reported to have the GAVE.30-32

The change of gastric antral motility and vasoactive materials may be expected to be involved in the mechanism of GAVE, but that is not clearly proved. Local treatment such as argon plasma coagulation therapy through endoscopic procedure can be applied for the management of GAVE.33 For the patients who are not effectively controlled by local therapy, the antrectomy or the hormone therapy such as estrogen or progesteron can be considered as additional treatment.30,31,34

CONCLUSION

Cirrhotic patients experience more frequent GI bleeding episodes compared with non-cirrhotic patients. Major causes of GI bleeding in cirrhotic patients are esophageal varix and gastric varix bleeding. Other causes are gastric and duodenal ulcer as similar with non-cirrhotic patients. Besides, PHG and GAVE are considered as other causes of GI bleeding in cirrhotic patients. The mechanisms of these two diseases are not clearly identified and their management can be different accordingly. So, more precise understanding of these conditions is still needed.

Conflicts of Interest

The author has no conflicts to disclose.

REFERENCES

1. Laine L. Rolling review: upper gastrointestinal bleeding. Aliment Pharmacol Ther 1993;7:207-232.
2. Rockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ 1995;311:222-226.
3. Sung JJ, Tsai KK, Ma TK, Yung MY, Lau JY, Chiu PW. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am J Gastroenterol 2010;105:84-89.
4. Czernichow P, Hochain P, Nousbaum JB, Raymond JM, Rudelli A, Dupas JL, et al. Epidemiology and course of acute upper gastrointestinal haemorrhage in four French geographical areas. Eur J Gastroenterol Hepatol 2000;12:175-181.
5. Christensen E, Fauerholdt L, Schlichting P, Juul E, Poulsen H, Tysstrup N. Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisone. Gastroenterology 1981;81:944-952.
6. Garden OJ, Motyl H, Gilmour WH, Utley RJ, Carter DC. Prediction of outcome following acute variceal haemorrhage. Br J Surg 1985;72:91-95.
7. Yeomans ND. The ulcer sleuths: The search for the cause of peptic ulcers. J Gastroenterol Hepatol 2011;26(Suppl 1):35-41.
8. Auroux J, Lamarque D, Roudot-Thoraval F, Deforges L, Chaumette MT, Richardet JP, et al. Gastroduodenal ulcer and erosions are related to portal hypertensive gastropathy and recent alcohol intake in cirrhotic patients. Dig Dis Sci 2003;48:1118-1123.
9. Siringo S, Burroughs AK, Bolondi L, Muia A, Di Febo G, Miglioli M, et al. Peptic ulcer and its course in cirrhosis: an endoscopic and clinical prospective study. J Hepatol 1995;22:633-641.
10. Vergara M, Calvet X, Roque M. Helicobacter pylori is a risk factor for peptic ulcer disease in cirrhotic patients. A meta-analysis. Eur J Gastroenterol Hepatol 2002;14:717-722.
11. Kim DJ, Kim HY, Kim SJ, Hahn TH, Jang MK, Baik GH, et al. Helicobacter pylori infection and peptic ulcer disease in patients with liver cirrhosis. Korean J Intern Med 2008;23:16-21.
12. Jung SW, Lee SW, Hyun JJ, Kim DI, Koo JS, Yim HJ, et al. Efficacy of Helicobacter pylori eradication therapy in chronic liver disease. Dig
Liver Dis 2009;41:134-140.
13. McCormack TT, Sims J, Eyre-Brook I, Kennedy H, Goepel J, Johnson AG, et al. Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy? Gut 1985;26:1226-1232.
14. Hashizume M, Tanaka K, Inokuchi K. Morphology of gastric microcirculation in cirrhosis. Hepatology 1983;3:1008-1012.
15. Lo GH, Yu HC, Chan YC, Chen WC, Hsu PI, Lin CK, et al. The effects of eradication of Helicobacter pylori on the recurrence of duodenal ulcers in patients with cirrhosis. Gastrointest Endosc 2005;62:350-356.
16. Tzathas C, Triantafyllou K, Mallas E, Triantafyllou G, Ladas SD. Effect of Helicobacter pylori eradication and antisecretary maintenance therapy on peptic ulcer recurrence in cirrhotic patients: a prospective, cohort 2-year follow-up study. J Clin Gastroenterol 2008;42:744-749.
17. Ripoll C, Garcia-Tsao G. Management of gastropathy and gastric vascular ectasia in portal hypertension. Clin Liver Dis 2010;14:281-295.
18. Perini RF, Camara PR, Ferraz JG. Pathogenesis of portal hypertensive gastropathy: translating basic research into clinical practice. Nat Clin Pract Gastroenterol Hepatol 2009;6:150-158.
19. Kim MY, Choi H, Baik SK, Yea CJ, Won CS, Byun JW, et al. Portal hypertensive gastropathy: correlation with portal hypertension and prognosis in cirrhosis. Dig Dis Sci 2010;55:3561-3567.
20. Pérez-Ayuso RM, Piqué JM, Bosch J, Panés J, González A, Pérez R, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 1991;337:1431-1434.
21. Zhou Y, Qiao L, Wu J, Hu H, Xu C. Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study. J Gastroenterol Hepatol 2002;17:973-979.
22. Mezawa S, Homma H, Ohta H, Masuko E, Doi T, Miyamori K, et al. Effect of transjugular intrahepatic portosystemic shunt formation on portal hypertensive gastropathy and gastric circulation. Am J Gastroenterol 2001;96:1155-1159.
23. Zullo A, Hassan C, Morini S. Helicobacter pylori infection in patients with liver cirrhosis: facts and fictions. Dig Liver Dis 2003;35:197-205.
24. Takeuchi Y, Kitano S, Bandoh T, Matsumoto T, Baatar D, Kato S. Acceleration of gastric ulcer healing by omeprazole in portal hypertensive rats. Is its action mediated by gastrin release and the stimulation of epithelial proliferation? Eur Surg Res 2003;35:75-80.
25. Ward EM, Raimondo M, Rosser BG, Wallace MB, Dickson RD. Prevalence and natural history of gastric antral vascular ectasia in patients undergoing orthotopic liver transplantation. J Clin Gastroenterol 2004;38:898-900.
26. Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion 2008;77:131-137.
27. Sebastian S, O’Morain CA, Buckley MJ. Review article: current therapeutic options for gastric antral vascular ectasia. Aliment Pharmacol Ther 2003;18:157-165.
28. Spahr L, Villeneuve JP, Dufresne MP, Tassé D, Bui B, Willems B, et al. Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. Gut 1999;44:739-742.
29. Leclerc S, Ben-Soussan E, Antonietti M, Goria O, Riachi G, Lerbourds E, et al. Bleeding gastric vascular ectasia treated by argon plasma coagulation: a comparison between patients with and without cirrhosis. Gastrointest Endosc 2008;67:219-225.
30. Tran A, Villeneuve JP, Bilodeau M, Willems B, Marleau D, Fenyes D, et al. Treatment of chronic bleeding from gastric antral vascular ectasia (GAVE) with estrogen-progesterone in cirrhotic patients: an open pilot study. Am J Gastroenterol 1999;94:2909-2911.